The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Hidemaru Yamaguchi - Citi Infrastructure Investments LLC - Analyst
: So good evening from Tokyo. Thank you very much for your presentations.
The first question is regarding the data you presented. There are so many data that has been presented, and especially the late stage of Phase 3
data is practically changing.
But in order for investors to digest what's going on, it's a little bit difficult to swallow because there are so many things that happen at the same
time. So if it's okay, Ken-san, can you give me, out of those, especially 3, 4 pivotal datas, which one do you think is really so-called practically changing
compared to the current therapy? Can you pick one or two out of all those things?
It's just your personal impression, thanks. That's the first question.
Question: Hidemaru Yamaguchi - Citi Infrastructure Investments LLC - Analyst
: Okay, thank you. The second question is regarding this 3939, which you gave us some preliminary data, and clearly, just look at the data. It looks
like ovarian cancer and lung cancer seems to be having more sort of response so far.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
OCTOBER 21, 2025 / 7:00AM, 4568.T - Daiichi Sankyo Co Ltd ESMO 2025 Highlights
But can you give me some idea where you're going to go from here as far as the cancer selection is concerned? Because my understanding is that
this is the so-called first Dai Sankyo 100% on asset, in the sense that you can choose whatever you want to, but at the same time, you have to be
careful about the current therapy or current alliance you have already.
So can you give me an idea where you're going to go for the selection of cancer, which you're going to go? Thank you.
Question: Hidemaru Yamaguchi - Citi Infrastructure Investments LLC - Analyst
: So you're kind of hinting so far there might be some chance, more chance maybe in lung cancer rather than any other areas because it's such a big
area to talk with.
|
